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Abstract:
Background: Sertraline is known to undergo changes in 
pharmacokinetics during pregnancy. CYP 2C19 has been implicated in 
the inter-individual variation in clinical effect associated with sertraline 
activity. However, knowledge of suitable dose titrations during 
pregnancy and within CYP 2C19 phenotypes is lacking. 
Methods: A pharmacokinetic modelling virtual clinical trials approach was 
implemented to: (i) assess gestational changes in sertraline trough 
plasma concentrations for CYP 2C19 phenotypes and (ii) to identify 
appropriate dose titration strategies to stabilise sertraline levels within a 
defined therapeutic range throughout gestation. 
Key Findings: Sertraline trough plasma concentrations decreased 
throughout gestation, with maternal volume expansion and reduction in 
plasma albumin being identified as possible causative reasons. All CYP 
2C19 phenotypes required dose increase throughout gestation. 
Conclusions: For extensive metaboliser (EM) and ultra-rapid metaboliser 
(UM) phenotypes, doses of 100-150 mg daily are required throughout 
gestation. For poor metabolisers (PM),       50 mg daily during trimester 
1 followed by a dose of 100 mg daily in trimesters 2 and 3 is required. 
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23 Background: Sertraline is known to undergo changes in pharmacokinetics during pregnancy. 
24 CYP 2C19 has been implicated in the inter-individual variation in clinical effect associated 
25 with sertraline activity. However, knowledge of suitable dose titrations during pregnancy and 
26 within CYP 2C19 phenotypes is lacking. 
27 Methods: A pharmacokinetic modelling virtual clinical trials approach was implemented to: 
28 (i) assess gestational changes in sertraline trough plasma concentrations for CYP 2C19 
29 phenotypes and (ii) to identify appropriate dose titration strategies to stabilise sertraline levels 
30 within a defined therapeutic range throughout gestation. 
31 Key Findings: Sertraline trough plasma concentrations decreased throughout gestation, with 
32 maternal volume expansion and reduction in plasma albumin being identified as possible 
33 causative reasons. All CYP 2C19 phenotypes required dose increase throughout gestation. 
34 Conclusions: For extensive metaboliser (EM) and ultra-rapid metaboliser (UM) phenotypes, 
35 doses of 100-150 mg daily are required throughout gestation. For poor metabolisers (PM),       
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43 Depression throughout pregnancy is known to affect up to 20 % of women (Fisher et al., 2012; 
44 Vigod, Wilson, & Howard, 2016), although fewer than 20 % of pregnant women will actually 
45 receive suitable treatment (Byatt, Xiao, Dinh, & Waring, 2016; Geier, Hills, Gonzales, Tum, 
46 & Finley, 2015).  The risk of untreated depression is particularly important given that death 
47 associated with suicide can affect 1 in every 25 women aged 20-35 years, from conception 
48 through to the post-natal period (J. J. Kim & Silver, 2016).  In addition, antenatal depression is 
49 a major risk factor for developing postnatal depression (McAllister-Williams et al., 2017).  A 
50 key strategy in the management of moderate-to-severe depression is the use of selective 
51 serotonin reuptake inhibitors (SSRIs) as first-line agents and which include sertraline, 
52 citalopram, fluoxetine, paroxetine and fluvoxamine. 
53 Sertraline is one of the most frequently used SSRIs globally, particularly during pregnancy 
54 (Bérard, Zhao, & Sheehy, 2017; Colvin, Slack‐Smith, Stanley, & Bower, 2011; Nordeng et al., 
55 2012; Oberlander et al., 2008; Ramos, Oraichi, Rey, Blais, & Berard, 2007; Reis & Kallen, 
56 2010; Zakiyah et al., 2018), and is commonly used to manage, amongst others, anxiety and 
57 panic disorders and obsessive-compulsive disorders (Pae & Patkar, 2007; Westin, Brekke, 
58 Molden, Skogvoll, & Spigset, 2017). Furthermore, SSRIs have been demonstrated to be lead 
59 to very few birth defects (Byatt, Deligiannidis, & Freeman, 2013).
60 Sertraline is metabolised by multiple Cytochrome P450 enzymes, including primarily CYP 
61 2C19 and 2B6 (Saiz-Rodríguez et al., 2018) along with contributions from CYP 2C9, CYP 
62 2D6 and CYP 3A4 (Obach, Cox, & Tremaine, 2005) and is a moderate inhibitor of CYP 2D6 
63 (Alfaro, Lam, Simpson, & Ereshefsky, 2000; Lam, Gaedigk, Ereshefsky, Alfaro, & Simpson, 
64 2002). Confounding the use of sertraline in pregnancy are the longitudinal changes in CYP 
65 isozyme expression during gestation, where expression increases for 2B6 (Koh et al., 2012), 
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66 2D6 (Stellan Högstedt, Lindberg, Peng, Regårdh, & Rane, 1985; S Högstedt, Lindberg, & 
67 Rane, 1983; Wadelius, Darj, Frenne, & Rane, 1997) and 3A4 (Kosel, Beckerman, Hayashi, 
68 Homma, & Aweeka, 2003; Prevost, Akl, Whybrew, & Sibai, 1992) and decreases for 2C19 
69 (McGready, Stepniewska, Edstein, et al., 2003; McGready, Stepniewska, Seaton, et al., 2003; 
70 Ward et al., 1991).  
71 The implications of such changes during gestation make dose optimisation challenging, and 
72 this is confounded by the paucity of the pharmacokinetic studies for sertraline use during 
73 pregnancy.  In those that have reported plasma concentrations during gestation, conflicting 
74 results indicate either an increase in trough plasma levels (Westin et al., 2017) necessitating 
75 possible dose reduction, or a decrease in plasma concentrations requiring a possible dose 
76 increase (M. P. Freeman et al., 2008; Marlene P. Freeman et al., 2008; Hostetter, Stowe, 
77 Strader, McLaughlin, & Llewellyn, 2000; Dorothy K. Sit, James M. Perel, Joseph C. Helsel, & 
78 Katherine L. Wisner, 2008; D. K. Sit, J. M. Perel, J. C. Helsel, & K. L. Wisner, 2008). The 
79 conflicting reports may, in part, be due to the complex metabolism route and longitudinal 
80 changes in the abundance of these enzyme pathways during gestation and often small sample 
81 (patient) sizes within studies.  Nevertheless, the consensus within all of these studies highlight 
82 the need for careful monitoring of depressive symptoms during the perinatal period.
83 Furthermore, CYP 2C19 is highly polymorphic and these genetic variabilities have been 
84 implicated in the requirement for dose adjustment in use of sertraline and other SSRIs with 
85 phenotypes of CYP 2C19  (Bråten et al., 2020; Hicks et al., 2015). Over 30 allelic variants have 
86 been identified for CYP 2C19 with the majority of patients being carriers of CYP 2C19 *1 
87 (extensive metaboliser [EM] trait), *2 (poor metaboliser [PM] trait), or *17 (ultra-rapid 
88 metaboliser [UM] trait) alleles.  Further, guidelines from the Clinical Pharmacogenetics 
89 Implementation Consortium (CPIC) (https://cpicpgx.org) detail the allele definitions and 
90 phenotypic interpretations of CYP 2C19 and their clinical relevance alongside providing 
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91 recommendations for genotype-guided dosing of sertraline, namely advocating a dose increase 
92 of at least 50 % in PM but no dose adjustment for UM phenotype patients.  However, 
93 conflicting reports on the impact of specific CYP 2C19 genotypes/phenotypes on sertraline 
94 have highlighted the need to investigate the impact of this further on dose adjustments (Bråten 
95 et al., 2020).
96 In the context of post-natal period, SSRIs have been reported to lead to Post Natal Adaptation 
97 Syndrome (PNAS).  This is, in part, due to their ability to cross the placenta which may result 
98 in increased serotonin concentrations in the developing fetus, thus; impacting fetal respiratory, 
99 cardiovascular and neurological development (Bérard et al., 2017; Byatt et al., 2013; Zakiyah 
100 et al., 2018).
101 A recent study implemented a pharmacokinetic modelling approach to explore the changes in 
102 sertraline concentrations through gestation (George et al., 2020). Whilst they also simulated a 
103 decrease in sertraline levels, their study lacked both the use of full body physiological model 
104 with a dedicated gestational-age dynamic fetal model and used a limited dataset for validation 
105 purposes. Given the limited pharmacokinetic data throughout pregnancy, the predominantly 
106 reported decrease in sertraline concentrations, coupled with its complex elimination pathways, 
107 we have applied, for the first time, a full body virtual clinical trials pharmacokinetic model to 
108 assess the dosing of sertraline throughout gestation to identity necessary dose titrations. 
109
110 With a focus on the existing guidelines for use of sertraline in CYP 2C19 phenotypes, the 
111 primary aim of this study was to: (i) evaluate the influence of gestation on plasma sertraline 
112 levels and (ii) provide a clinically relevant dosing titration strategy for CYP 2C19 phenotype 
113 status during gestation.  
114
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115 2. METHODS 
116 We utilised the Simcyp Simulator, a physiologically-based pharmacokinetic (PBPK) modelling 
117 tool, to conduct virtual clinical trials simulations (Simcyp Ltd, a Certara company, Sheffield, 
118 UK, Version 17).  Unless otherwise stated, we incorporated mixed genders (50:50) into all 
119 simulations.  We utilised a four-stage workflow (Figure 1).
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121 Figure 1.  A workflow modelling approach for sertraline 
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122 2.1 Step 1: Validation of sertraline
123 We utilised the Simcyp ‘healthy volunteer’ (HV) population group for studies with baseline 
124 populations consisting of non-pregnant females.  For pregnant population groups we used the 
125 Simcyp ‘pregnancy’ population.  This population was developed previously by Simcyp 
126 researchers and includes gestation dependant changes in physiology, cardiac output, tissue 
127 perfusion, blood volume alongside biochemistry modification (e.g. human serum albumin) and 
128 enzyme/protein expression (Abduljalil, Furness, Johnson, Rostami-Hodjegan, & Soltani, 2012; 
129 De Sousa Mendes et al., 2015; Jogiraju, Avvari, Gollen, & Taft, 2017; Lu et al., 2012).  
130 Sertraline is not available within the Simcyp Simulator, however a previous study developed 
131 and validated a sertraline compound for use within the Simcyp simulator (Templeton et al., 
132 2016), with modifications made by our group to allow its use during gestation.   
133
134 In order to apply this previously validated model within the context of our studies, 5 
135 retrospective clinical studies were employed, 4 single dose studies and 1 multiple dose studies: 
136 (i) 24 healthy adults (12 male and 12 female) aged between 18-45 years old dosed a single oral 
137 dose of 50 mg sertraline (Niyomnaitham, Chatsiricharoenkul, Sathirakul, Pongnarin, & 
138 Kongpatanakul, 2009) (ii) 18 healthy subjects administered a single 50 mg oral dose of 
139 sertraline (X. Chen, Duan, Dai, & Zhong, 2006); (iii) 5 healthy male volunteers, mean age 26.1 
140 years ± 4.2 years, administered a 50 mg single dose of sertraline (K. M. Kim et al., 2002); (iv) 
141 5 male and 5 female (19-31 years) dosed 100, 200 and 400 mg as a single dose with Cmax 
142 reported (Saletu, Grunberger, & Linzmayer, 1986) and (v) 11 male and 11 female healthy 
143 volunteers aged between 18-45 years old administered a 200 mg daily for 30 days, with 
144 sampling on day 30 (Ronfeld, Tremaine, & Wilner, 1997); The design of trials within Simcyp 
145 were matched to these clinical studies.  Simcyp Simulator parameters for sertraline are detailed 
146 in the Supplementary Materials (Section 1: Table S1).
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147 2.2 Step 2: Validation of sertraline during pregnancy
148 In order to apply the developed sertraline model during pregnancy, we conducted further 
149 validation using data extracted from a retrospective analysis of therapeutic drug monitoring 
150 services in Norway (Westin et al., 2017).  This study included 56 pregnant and 52 non-pregnant 
151 (female) sertraline plasma concentrations, obtained from 34 women taking an oral dose of 50 
152 mg daily. Importantly, this study reported individualised sample data throughout gestation 
153 rather than a central tendency without variance (Dorothy K. Sit et al., 2008), missing patient 
154 sample data throughout study or poor sample sizes (M. P. Freeman et al., 2008).
155 The Simcyp Pregnancy model has been utilised previously to assess changes in plasma 
156 concentration in pregnant women (Jogiraju et al., 2017; Ke, Greupink, & Abduljalil, 2018; 
157 Olafuyi & Badhan, 2019) and this study represents its application in the context of sertraline 
158 for the first time. The Simcyp Pregnancy model changes the physiology of the mother (e.g. 
159 tissue volumes) throughout the study period, which allows the model to operate in a dynamic 
160 nature, updating the prediction of Vss through the study as a result of updated estimates of the 
161 tissue-partition coefficient (Kp), as opposed to using fixed estimates of Kp and Vss.
162 The Simcyp Pregnancy model does not inherently include longitudinal changes in CYPs 2C19 
163 and 2B6, and these were incorporated based on previous reports of successful implementation 
164 within the Simcyp Simulator (Almurjan, Macfarlane, & Badhan; Ke et al., 2018) 
165 (Supplementary Materials (Section 2). In order to replicate the study by Westin et al (Westin 
166 et al., 2017) we utilised a 38-week gestation and 10 x 10 (n=100 subject) study design with 
167 sertraline doses of 50 mg daily. Data was collected for every 5th week and presented as the final 
168 24 hours of that period. A similar trial design was implemented for non-pregnant females 
169 (baseline).
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170 2.3 Step 3: Impact of CYP 2C19 polymorphism on sertraline plasma concentration 
171 during pregnancy
172 Sertraline plasma concentrations are known to be altered in different CYP 2C19 phenotypes 
173 (Hicks et al., 2015).  In order to simulate the impact of CYP 2C19 phenotypes in pregnant 
174 women, we simulated entirely extensive metaboliser (EM), poor metaboliser (PM) and ultra-
175 rapid metaboliser (UM) populations through revision of the default phenotype distribution to 
176 ensure uniform phenotype populations.  For each phenotype, CYP 2C19 enzyme abundance 
177 was also incorporated and detailed in the Supplementary Materials (Section 2).
178 Study design implemented a 10x10 trial design with a daily dose of 50 mg once daily 
179 throughout gestation and sampling (of plasma concentration) conducted for every 5th week and 
180 presented as the final 24 hours of that period. Where appropriate, data was also presented on 
181 the final dosing day of the week during trimester 1 (T1: week 10), trimester 2 (T2: week 20) 
182 and trimester 3 (T3: week 30).  
183 In the absence of any published data, the default value of 0 pmol/mg was used for CYP 2C19 
184 PM phenotypes within the Simcyp Simulator (Djebli et al., 2015; Gong, Iacono, Iyer, 
185 Humphreys, & Zheng, 2018). 
186 2.4 Step 4: Dose adjustment during gestation
187 To explore approaches to sertraline dose titration during gestation on resultant plasma 
188 concentrations, dosing was initiated at 50 mg once daily and increased in weekly increments 
189 by 50 mg to a maximum of 300 mg once daily.  A proposed therapeutic range was set at 10-75 
190 ng/mL (Bråten et al., 2020). This was based on reports from the Arbeitsgemeinschaft für 
191 Neuropsychopharmakologie und Pharmakopsychiatrie’ (AGNP) suggesting a range of                  
192 30-500 nM (Hiemke et al., 2018), equating to a lower limit of approximately 10 ng/mL.  The 
193 upper limited was defined by Bråten et al in relation to the concentration of sertraline occurring 
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194 the serotonin transporter (SERT) and being approximately 250 nM (~75 ng/mL) (Bråten et al., 
195 2020; Mauri et al., 2003).
196 Data was reported for each phenotype studied, namely EM, PM and UM subjects, on the final 
197 day of each trimester and presented as the percentage of subjects possessing trough plasma 
198 concentrations outside of the therapeutic range (i.e. below 10 ng/mL and above 75 ng/mL).
199 2.5 Predictive performance
200 To ensure appropriate predictive performance (Steps 1-2), predictions of pharmacokinetic 
201 metrics that were within two-fold (0.5-2.0 fold) of published data was accepted as part of the 
202 ‘optimal’ predictive performance (Edginton, Schmitt, & Willmann, 2006; Ginsberg, Hattis, 
203 Russ, & Sonawane, 2004; Parrott et al., 2011).  Furthermore, predictions in step 1-2 were also 
204 validated using a visual predictive checking (VPC) strategy (U.S. Food and Drug 
205 Administration, 2012) when compared to reported data. This approach compared the Simcyp 
206 Simulator predicted concentration–time profiles, which consisted of either a mean or median 
207 and the 5th and 95th percentiles, against the observed data.  A successful validation approach 
208 was assumed when Simcyp-predicted results overlapped with the observed data sets (Almurjan 
209 et al.; Olafuyi & Badhan, 2019).
210
211 2.7 Data and statistical analysis
212 Retrospective (observed) clinical data was extracted from reported studies using 
213 WebPlotDigitizer v.3.10 (http://arohatgi.info/WebPlotDigitizer/). Tabulated (observed) 
214 clinical data was utilised as reported in studies, namely mean and standard deviation (Step 1 
215 and 2).  Exploratory studies (Step 3 and 4) were reported as median and range, unless otherwise 
216 stated.  Statistical analysis was conducted using a non-parametric Kruskal-Wallis test with a 
217 Dunn’s multiple comparison post-hoc test. Significance was confirmed with a p < 0.05. All 
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218 statistical testing was conducted using GraphPad Prism version 8.00 for Windows (GraphPad 
219 Software, La Jolla California USA, www.graphpad.com).
220 3. RESULTS
221 3.1 Step 1: Validation of sertraline
222 A previously reported sertraline model (Templeton et al., 2016) was adapted, implementing a 
223 full-PBPK model in order to appropriately model physiological changes during gestation and 
224 their impact upon Vss. The model was validated against 4 single dose studies, 1 multiple dose 
225 study and a dose escalation study.  The resulting predicted plasma concentration-time profiles 
226 successfully predicted single dose (Figure 2A), multiple dose (Figure 2B) and dose escalation 
227 studies (Figure 2C).  Furthermore, the resultant Simcyp predicted tmax, Cmax, and AUC were 
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234 Figure 2.  Simulated sertraline plasma concentrations 
235 (A) Single 50 mg oral doses of sertraline (X. Chen et al., 2006; K. M. Kim et al., 2002; 
236 Niyomnaitham et al., 2009); (B) Multiple daily 50 mg oral doses reported on day 30 (Ronfeld 
237 et al., 1997) for males (red) and females (green); (C) 100, 200 and 400 mg single doses of 
238 sertraline (Saletu et al., 1986); (D)  Forest plot showing the predicted mean ± SD over the 
239 observed ratio of pharmacokinetic parameters in subjects, with the dotted and shaded area 
240 representing the 2-fold range [0.5 to 2] and solid black line the line of unity.  For (A) and (B) 
241 solid circles represent observed clinical data with error bars indicating standard deviation, solid 
242 lines represent predicted mean concentration-time profile and the 5th and 95th percentile range 
243 represented by dotted lines.  For (C), solid red circles represent observed clinical data with 
244 upper and lower red lines indicating standard deviation. Solid black square and error bars 
245 indicate mean and standard deviation respectively.
246
247 3.2 Step 2: Validation of sertraline during pregnancy
248 The distribution of simulated sertraline plasma concentrations were similar to the range of 
249 observations reported (Westin et al., 2017) during pregnancy (Figure 3). The predicted mean 
250 plasma concentration in non-pregnant females (baseline), 16.20 ng/mL ± 10.32 ng/mL, was 
251 within 2-fold of that reported, 11.1 ng/mL ± 7.02 ng/mL (Westin et al., 2017).  Further when 
252 compared to baseline, plasma concentrations decreased for trimester 2 (week 15: 16.13 ng/mL 
253 ± 9.71 ng/mL, week 20: 15.01 ng/mL ± 9 ng/mL) and trimester 3 (week 30: 14.41 ng/mL ± 
254 8.59 ng/mL, week 35, 13.68 ng/mL ± 8.13 ng/mL ).  The decrease from baseline was only 
255 statistically significant for week 35 (p = 0.021).
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257 Figure 3.  Model predicted and observed plasma concentrations of sertraline throughout 
258 pregnancy 
259 Predicted concentrations were obtained from subjects (n=100) administered a 50 mg daily dose 
260 and data collected as post-dose (trough concentrations) sampled on the final 24 hours period 
261 after dosing and collated every 5-weeks (black open circles). Sertraline concentrations in non-
262 pregnant female are illustrated as ‘Baseline’. Red open circles represent pooled (observed) 
263 plasma concentrations obtained from a total of 34 subjects. The therapeutic window is 
264 represented by the shaded regions between 10 ng/mL to 75 ng/mL. Blue horizontal lines 
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272 3.3 Step 3: Impact of CYP 2C19 polymorphism on sertraline plasma concentrations 
273 during pregnancy
274 CYP 2C19 is highly polymorphic and the primary metabolic pathway for sertraline.  Changes 
275 in trough concentrations and intrinsic clearance was assessed for baseline and during gestation 
276 for CYP 2C19 phenotype subjects, using frequencies reported within Simcyp Simulator (EM: 
277 59 %, PM: 9.2 % and UM: 31.8 %).
278 The median trough plasma concentration decreased for by 17.2 % (EM, p < 0.001), 14.4 % 
279 (PM, p < 0.05) and 20 % (UM, , p < 0.001) by week 30 when compared to baseline (Figure 4) 
280 (Supplementary Materials: Section 3 Table S2).
281
282 Figure 4.  Simulated sertraline trough plasma concentrations for CYP 2C19 polymorphs.
283 The impact of pregnancy on sertraline trough (Cmin) plasma concentrations for CYP 2C19 
284 extensive metabolisers (EM) and poor metabolisers (UM) in non-pregnant females (baseline) 
285 and throughout pregnancy following a 50 mg once daily dose to 100 subjects per phenotype. 
286 Data represent by box and whisker plots with median, 5th and 95th percentiles detailed. *p<0.05, 
287 **p<0.01, ***p<0.001.
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288 Despite decreases in trough plasma concentrations throughout gestation, CYP 2C19 intrinsic 
289 clearance also decreased. For EMs, a decrease in the median Clint by CYP 2C19 was noticed 
290 from the 1st trimester (week 5: 78.4 L/h [17.5-611 L/h]) and continued to decrease in weeks 10 
291 and 15: 68.5 L/h [13.8-533.8 L/h], 63.8 L/h [13.3-513.7 L/h], respectively, when compared to 
292 the baseline Clint, 78.4 L/h [17.5-622.1 L/h]. Statistically significant decreases in Clint were 
293 apparent from gestational week (GW) 20 onwards when compared to baseline subjects 
294 (p<0.05) (Figure 5) (Supplementary Materials: Section 4 Table S3). 
295 For UMs, a decrease in the median Clint by CYP 2C19 was also noticed from the 1st trimester 
296 (week 5: 97.5 L/h [21.7-721.6 L/h] and continued to decrease in weeks 10 and 15, 90.4 L/h 
297 [20.1-671.7 L/h] and 83.3 L/h [18.5-618.7 L/h], respectively, when compared to the baseline 
298 Clint, 105.17 L/h [24.5-776.3 L/h]. Statistically significant decrease in Clint was apparent from 
299 gestational week (GW) 20 onwards when compared to non-pregnant subjects (p<0.05) (Figure 
300 5) (Supplementary Materials: Section 4 Table S3).
301
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303 Figure 5. The impact of CYP 2C19 polymorphism on sertraline clearance throughout 
304 pregnancy 
305 The impact of CYP 2C19 extensiv  metaboliser (EM) and ultra-rapid metaboliser (UM) 
306 phenotypes on Simcyp predicted sertraline in-vivo intrinsic clearance for non-pregnant females 
307 (baseline) and during pregnancy, following a 50 mg once daily dose to 100 subjects per 
308 phenotype. Data represent by box and whisker plots with median, 5th and 95th percentiles 
309 detailed. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
310
311 3.4 Step 4: Sertraline dose optimisation
312 In order to address changes in sertraline concentrations during gestation for CYP 2C19 
313 phenotype subjects, we quantified the percentage of subjects with plasma concentrations 
314 outside of the therapeutic range (i.e. below 10 ng/mL and above 75 ng/mL) across a dosing 
315 range of 50-300 mg daily.  
316 Regardless of the phenotype, the daily sertraline dose required to maintain trough 
317 concentrations within the therapeutic window was above the usual 50 mg/day throughout 
318 pregnancy. When attempting to identify an optimal dose, we ensured a balance of a low 
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319 percentages of subjects outside of this window, with an optimal dose defined as where no more 
320 than 20 % of subjects possessed concentrations outside of the window (Figure 6) 
321 (Supplementary Materials: Section 5 Table S4).
322 For EM and UM, a dose of 100-150 mg daily is suggested to be optimal throughout pregnancy.  
323 For PM, a starting dose of 25 mg once daily resulted in a > 60 % of subjects with trough levels 
324 below 10 ng/mL across pregnancy (Figure 6).  However, a dose of 50 mg once daily resulted 
325 in 24 % of subjects possessing trough levels below 10 ng/mL (Figure 6).  During trimesters 2 
326 and 3, an increase in dose to 100 mg once daily resulted in less than 10 % of the subjects 
327 demonstrating trough levels below 10 ng/mL (Figure 6) (Supplementary Materials: Section 5 
328 Table S4).
329
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333 Figure 6. Dose optimisation of sertraline during pregnancy in CYP 2C19 phenotyped 
334 subjects
335 Doses were titrated in increments of 50 mg every 3 days over a range of 50 mg to 300 mg once 
336 daily throughout pregnancy.  Trough plasma concentrations were reported for the final dosing 
337 day of each trimester in specific EM, PM or UM pregnancy population groups. Percentages of 
338 subjects with plasma concentration (trough) outside of the therapeutic range (below 10 ng/mL 
339 [left panels] and above 75 ng/mL [right panels]) are reported.
340  
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342 Depression is a leading cause of disability worldwide (World Health Organization, 2008), and 
343 is thought to affect more than 20 % of pregnant women (Fisher et al., 2012; Gaynes et al., 2005; 
344 Vigod et al., 2016).  A key challenge for healthcare professional is the use of pharmacological 
345 interventions during pregnancy, which is often informed by balancing the expected benefits for 
346 the mother’s mental health with the possible risks to the foetus. This decision is further 
347 complicated by gestational related alterations in maternal physiology (Isoherranen & 
348 Thummel, 2013) which can impact upon the pharmacokinetics of drugs. Often the combined 
349 impact of these, in additional to the longitudinal nature of these alterations, make it difficult to 
350 extrapolate their impact during clinical practice (Tracy, Venkataramanan, Glover, Caritis, & 
351 Units, 2005). To augment the existing empirical approaches to treatment interventions, the 
352 application of robust and well validated pharmacokinetic models offers a unique opportunity 
353 to apply virtual clinical trials to support medicines optimisation in mental health for special 
354 population groups. 
355 Sertraline is metabolised by multiple enzymes, including CYPs 2C19, 2B6, 2C9, 3A4 and 2D6. 
356 Confounding the use of sertraline in pregnancy, is the gestational alterations in maternal CYP 
357 2C19 activity, which has been determined to decrease by 62 % and 68 % during trimester 2 
358 and 3 respectively (McGready, Stepniewska, Edstein, et al., 2003; McGready, Stepniewska, 
359 Seaton, et al., 2003; Ward et al., 1991).  Despite this decrease, several confounding  studies 
360 have noticed either an apparent decrease (M. P. Freeman et al., 2008; Hostetter et al., 2000; D. 
361 K. Sit et al., 2008) or increase (Westin et al., 2017) in sertraline plasma concentrations during 
362 gestation.
Page 22 of 56
http://mc.manuscriptcentral.com/bdd
















































































363 In this study, we have applied virtual clinical trials dosing of sertraline throughout pregnancy, 
364 to identity suitable dose titration necessary to support therapeutically maintained sertraline 
365 plasma concentrations in the mother throughout pregnancy. 
366
367 We adapted a previously published sertraline model (Templeton et al., 2016) to allow its use 
368 within the context of gestation, and this was fully validated with both single and multiple dose 
369 studies in both pregnant and non-pregnant subjects, with predictions to 2-fold of those reported 
370 (Figure 2) (Supplementary Materials: Section 3 Table S1) and spanning a similar range within 
371 the population studies (Figure 2). However, a wider AUC range in the predicted-observed ratios 
372 (Figure 2D), although still within 2-fold, are thought to be a reflection of the complexity 
373 associated with the metabolism of sertraline, namely CYPs 2C9, 2C129, 2B6, 2D6 and 3A4 
374 and hence the associated contribution towards inter-individual variability. The variance in 
375 AUC from clinical studies (measured as mainly the standard deviation) was broadly similar to 
376 those simulated within our studies (See Supplementary Materials Section 3).
377 A recent report by Westin et al (Westin et al., 2017) highlighted sertraline plasma 
378 concentration throughout gestation in 34 subjects. This was used as the basis for validation of 
379 the pregnancy PBPK model. The resulting mean plasma concentrations in non-pregnant 
380 subjects (16.20 ng/mL ± 10.32 ng/mL) were within 2-fold of those reported (Westin et al., 
381 2018) and also demonstrated a similar predicted range to that reported (Figure 3). Furthermore, 
382 we demonstrated a decrease in mean plasma concentration throughout pregnancy with a 
383 significant decrease in GW35 (p<0.05) compared to baseline (Figure 3). On the contrary, a      
384 10 %, 36 % and 68 % increase in plasma concentration were reported by Westin et al (Westin 
385 et al., 2017) during trimesters 1-3 respectively.  Other studies have identified a similar decrease 
386 to that reported here (M. P. Freeman et al., 2008) (Dorothy K. Sit et al., 2008), however Westin 
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387 et al (Westin et al., 2017) included individualised sample data throughout gestation rather than 
388 a central tendency without variance (Dorothy K. Sit et al., 2008), missing patient sample data 
389 throughout the study or utilising poor sample sizes (M. P. Freeman et al., 2008).  Nonetheless, 
390 to further examine the reported disparity in clinical observations, we assessed changes in trough 
391 plasma concentrations and intrinsic clearance as a result of population variability in the 
392 phenotypes of one of the primary CYP isozyme responsible for sertraline metabolism, namely 
393 CYP 2C19.  In all tested phenotypes, the intrinsic clearance decreased throughout pregnancy, 
394 mirroring decreases in CYP 2C19 activity, the largest significant difference in clearance being 
395 noticed in trimester 3 (Supplementary Materials: Section 4 Table S3). 
396 This decrease in clearance was expected to increase sertraline trough plasma concentrations as 
397 observed by Westin et al (Westin et al., 2017). On the contrary, trough plasma concentrations 
398 for EMs and UMs decreased during gestation with the greatest significant decrease occurring 
399 in trimester 3 (Figure 6), which concurred with a range of other reports (M. P. Freeman et al., 
400 2008; Schoretsanitis et al., 2020; D. K. Sit et al., 2008; Tracy et al., 2005; Ververs et al., 2009). 
401 This decrease has been associated with an increase in the key female hormones estradiol and 
402 progesterone throughout pregnancy, with concentrations reaching up to 100 nM and 1 μM for 
403 estradiol and progesterone, respectively, at term.  These levels are significantly greater than 
404 those during menstruation (< 50 nM) (Cunningham, Leveno, Bloom, Spong, & Dashe, 2014; 
405 Holinka, Diczfalusy, Bennink, & biology, 2008). Such female hormones are known to be 
406 activators for basic helix-loop-helix transcription factors (e.g. aryl hydrocarbon receptor; AhR) 
407 or nuclear hormone transcriptional regulators (constitutive androstane receptor, CAR; 
408 pregnane X receptor, PXR; estrogen receptor, ER), which contribute to the induction of a 
409 variety of CYP isoforms and enhanced drug clearances (H. Chen, Yang, Choi, Fischer, & 
410 Jeong, 2009; Jeong, Choi, Song, Chen, & Fischer, 2008).  However, the metabolic breakdown 
411 of sertraline is complicated, and includes CYPs 2B6, 2C9, 2C19, 2D6, and 3A4. The 
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412 contribution of each isozyme has proven difficult to determine in-vivo, however the variable 
413 up- or down-regulation of CYP isozyme expression during gestation (Abduljalil & Badhan, 
414 2020) may contribute to the disparity observed in some studies (Westin et al., 2017).  For 
415 example, the approximate 2-fold decrease in 2C19 activity coupled with approximately 2-fold 
416 increase in 2B6 activity by trimester 3 may negate the overall impact of each pathway, in 
417 preference to changes in other physiological factors such as increases in total body water.  
418 Furthermore, the concomitant decrease in albumin is likely to cause the observed increase in 
419 sertraline plasma unbound fraction and hence increase the volume of distribution, extending 
420 the half-life and reducing sertraline plasma levels. To confirm this, a global sensitivity analysis 
421 (GSA) was implemented to examine the combined influence of albumin levels, CYPs 2C19 
422 and 2B6 abundance on Cmax, AUC, Cl and Vss (Supplementary Materials: Section 6) within 
423 the model.  The resulting model sensitivity rankings (Supplementary Materials: Section 6 Table 
424 S5), confirmed the sensitivity of the model to changes in human serum albumin levels 
425 throughout gestation and primarily in trimester 3 (Supplementary Materials: Section 6 Table 
426 S6).  Given that sertraline is highly protein bound, the decrease in albumin during pregnancy 
427 would be significant driver for reduced plasma levels and an extension of the half-life (Little 
428 & Gynecology, 1999), potentially more so that the impact of CYP isozyme gestational changes.
429 At present, there is a paucity of studies exploring the impact of CYP 2C19 phenotypes 
430 on sertraline levels during pregnancy. A recent dosing guideline for sertraline which considered 
431 CYP 2C19 phenotypes has been published (Hicks et al., 2015). However, it is not clear whether 
432 the proposed guidelines are relevant to pregnant women. Given the importance of the 
433 phenotype of the subject on gestational sertraline levels, we next examined the changes in the 
434 trough levels in relation to the therapeutic range of sertraline under a standard 50 mg daily 
435 dosage of sertraline (Bråten et al., 2020).  As expected, the UM phenotypes demonstrated the 
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436 largest number of subjects below 10 ng/mL (Supplementary Materials: Section 5 Table S4), 
437 whereas for the PM group, this was predicted to be in the range of 24-31 %. 
438 Finally, for all phenotypes (EM, PM and UM), dose titrations were required to daily doses that 
439 were typically in excess of the 50 mg dose throughout pregnancy. For EM and UM, a dose 
440 escalation to 100-150 mg daily is suggested to be optimal through pregnancy. For PM, a dose 
441 of 50 mg during the first trimester followed by a dose increase in trimesters 2 and 3 to 100 mg 
442 is suggested to be optimal. Furthermore, the doses suggested within this study are within the 
443 range clinical utilised and significantly below the know toxicity range in adults (> 4000 
444 mg/daily) (Lau & Horowitz, 1996).  The return of maternal sertraline plasma levels would be 
445 needed post-natally and although this is not possible to simulate within Simcyp, tapering the 
446 dose of sertraline by 50 mg per 5-7 days is recommended to avoid withdrawal syndrome 
447 (Shelton & Richard, 2001). Furthermore, although there is very little published studies 
448 reporting pharmacodynamic changes during pregnancy for sertraline, the current approaches 
449 for the studies during pregnancy focus primarily on the clinicians role in the dose titration based 
450 on empirical changes in the psychiatric state of the patient (Ornoy & Koren, 2019). In addition, 
451 although clinicians routinely monitor drug pharmacodynamics by directly measuring 
452 physiological indices of therapeutic responses, the link between (unbound) plasma levels and 
453 clinical response is not well established for sertraline (Bergink et al., 2011; Cox, Holden, & 
454 Sagovsky, 1987; Sachs, Guille, & McMurrich, 2002).  Further, any attempt to relate unbound 
455 levels to a pharmacodynamic effect would need to further consider that the resultant central 
456 effects would be governed by the blood-brain barrier, which acts as a permeability barrier to 
457 any resultant central effects on reuptake of monoamines into the presynaptic neurones.  Further 
458 work is needed to address the reductions in sertraline plasma concentration through gestation 
459 on the resultant maternal pharmacodynamic effects on mood stability, in order to fully translate 
460 the results presented within this manuscript to clinical practice.
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461 A key benefit of the pregnancy PBPK approach highlighted within our study, is the 
462 ability to incorporate key gestational changes in the physiology of the mother, for example the 
463 highlight reduction in plasma albumin and increase in maternal volume, which can be coupled 
464 with a mechanistic description of the activities of metabolising enzyme to enable disentangling 
465 what would otherwise be clinically complicated relationships.
466 5. CONCLUSION
467 Any decision to withdraw or continue with antidepressant therapy perinatally is challenging 
468 for both maternal and fetal health.  A key paradigm is the balance between the benefit of 
469 continuing treatment and the risk drug-related toxicity to the developing embryo/foetus.  
470 Confounding treatment during gestation, are longitudinal maternal physiological alternations 
471 which alter the requirements for dosing.  Furthermore, the susceptibility of CYP 2C19 to 
472 polymorphisms only increases the complexity in prescribing decisions. 
473 Our results demonstrated that dose titrations are required throughout pregnancy, with UM 
474 subjects being of concern and requiring at least double the standard dose by trimester 3, to 
475 support on-going maintenance of plasma sertraline concentrations to within the therapeutic 
476 range. 
477 This study has highlighted a key role for the use of pharmacokinetics to allow pragmatic 
478 exploration of dosing regimens within a perinatal setting, to support the reduction in risk of 
479 treatment relapse due to inappropriate dosing. 
480
481
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